Xbrane Biopharma, a Swedish biotechnology company, says it is starting its phase 3 trial of its ranibizumab biosimilar, referencing Lucentis, and also set sales targets for the treatment for patients with wet age-related macular degeneration.
Xbrane Biopharma, a Swedish biotechnology company, says it is starting its phase 3 trial of its ranibizumab biosimilar, referencing Lucentis, and also set sales targets for the treatment for patients with wet age-related macular degeneration (AMD).
Xbrane expects the first revenues from Xlucane sales during the first quarter 2022. Its co-development and commercialization partner is Stada Arzneimittel AG.
This is the first proposed biosimilar studied by Xbrane after it announced in September 2018 that the company was shifting its focus from generic drugs to biosimilars.
Xbrane’s target is to reach €350 (USD $392.65) million in annual net sales 3 years after the product’s launch. This renders approximately €100 (USD $112.15) million in annual license income for Xbrane, after deduction of production and sales related expenses and profit sharing with Stada.
The sales target is based on reaching a volume market share of 25% in Europe and the United States of the ranibizumab market at a price discount in line with recent biosimilar product launches. During 2018, the brand-name Lucentis’ global sales amounted to €3.5 (USD $3.93) billion.
Ranibizumab is an anti-vascular endothelial growth factor (VEGF) therapy. Other companies working on ranibizumab biosimilars include Coherus BioSciences and Samsung Bioepis.
“We strongly believe in the commercial prospects of Xlucane. There is a great need for more cost-efficient products in the ophthalmic VEGF inhibitor market, and I am confident that Xlucane will be received positively by the ophthalmology community and patients,” Martin Åmark, Xbrane’s chief executive officer, said in a statement.
The Xplore trial is designed as a phase 3 trial to confirm biosimilarity of the proposed biosimilar to the reference product in terms of safety, efficacy, and immunogenicity. The study will look to enroll about 600 patients across 150 sites in 16 countries. The primary end point is defined as the change in visual acuity after 8 weeks of treatment. In order to measure this success, the confidence interval of the difference between the proposed biosimilar and the reference will need to fall within a predefined equivalence margin.
According to the American Macular Degeneration Foundation, the wet type of AMD accounts for 10% to 15% of AMD. Abnormal blood vessels, called choroidal neovascularization or CNV, grow under the retina and macula and then bleed and leak fluid. As the macula bulges or lifts up from its normally flat position, central vision is distorted or destroyed.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.